Literature DB >> 3292375

The development of high dose melphalan and of autologous bone marrow transplantation in the treatment of multiple myeloma: Royal Marsden and St Bartholomew's Hospital studies.

P Selby1, G Zulian, G Forgeson, A Nandi, S Milan, M Meldrum, C Viner, R Osborne, J S Malpas, T J McElwain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3292375     DOI： 10.1002/hon.2900060218

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN： 0278-0232            Impact factor:   5.271


× No keyword cloud information.
  8 in total

Review 1.  Multiple myeloma: current treatment.

Authors:  D Samson
Journal:  Postgrad Med J       Date:  1994-06       Impact factor: 2.401

Review 2.  Problems in the management of myeloma.

Authors:  J S Malpas
Journal:  Postgrad Med J       Date:  1989-07       Impact factor: 2.401

Review 3.  Role of autologous stem cell transplantation in multiple myeloma.

Authors:  Shaji Kumar
Journal:  Curr Hematol Malig Rep       Date:  2007-05       Impact factor: 3.952

4.  Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan.

Authors:  Ping Zhou; Julie Teruya-Feldstein; Ping Lu; Martin Fleisher; Adam Olshen; Raymond L Comenzo
Journal:  Blood       Date:  2007-11-02       Impact factor: 22.113

5.  Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies.

Authors:  Brian L Burnette; Angela Dispenzieri; Shaji Kumar; Ann M Harris; Jeff A Sloan; Jon C Tilburt; Robert A Kyle; S Vincent Rajkumar
Journal:  Cancer       Date:  2013-09-19       Impact factor: 6.860

6.  Melphalan transport into human malignant lymphoid cells differs from the murine equivalent in vitro.

Authors:  B C Millar; J A Maitland; J L Millar; J B Bell
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

7.  Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma.

Authors:  B Sirohi; R Powles; S Kulkarni; C Rudin; R Saso; A Rigg; C Horton; S Singhal; J Mehta; J Treleaven
Journal:  Br J Cancer       Date:  2001-08-03       Impact factor: 7.640

Review 8.  Potential of oncolytic viruses in the treatment of multiple myeloma.

Authors:  Eric Bartee
Journal:  Oncolytic Virother       Date:  2018-02-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.